Home
NewsNewsINVO Fertility would be introducing time-lapse incubation technology at its Wisconsin clinic, hence offering high-quality lab care, creative patient solutions, and advanced embryo monitoring for improved fertility results.
INVO Fertility, Inc., a healthcare services fertility company that helps people get advanced reproductive treatment by setting up, acquiring as well as running fertility clinics along with related businesses and technologies, on March 5, 2026, went ahead and announced that its Wisconsin clinic would start using time-lapse incubation technology. This integration shows that INVO is indeed dedicated to providing modern, high-quality lab care and creative patient solutions, as well as to improving the quality of labs and clinics across its growing network.
According to COO of INVO, April McGhee, “INVO Fertility is proud to introduce this time-lapse incubation technology as part of our ongoing focus on quality and innovation and the expansion of additional patient service offerings. This technology enhances the tools available to our embryology teams while aligning with our commitment to delivering thoughtful, patient-centred fertility care.”
INVO is looking out to improve its clinics and help its clinical and laboratory teams and also throttle its mission of providing accessible, patient-centred fertility care by using proven new ideas like time-lapse incubation. This adoption shows that the company is keeping its promise to invest in cutting-edge technologies that improve the treatment journey for patients. It is also part of the company's larger plan to responsibly integrate cutting-edge reproductive technologies that provide real value to patients and doctors.
Remarks CEO Steve Shum, “Our approach to innovation is intentional. We focus on technologies that may enhance quality and outcomes while staying true to our mission of expanding access to fertility care through continuous, responsible innovation.”
A groundbreaking Nature Medicine study compares AI deep learning against expert embryologists in selecting embryos. While pregnancy rates remain comparable, the study uncovers a massive advantage in efficiency that could revolutionize IVF labs worldwide. Discover how AI-driven embryo selection accuracy is reshaping the future of fertility treatment.
FertilAI has received EU MDR clearance for tools advancing Predictive AI in Fertility through its Fertilane platform. StimAI and OvuPredict help clinicians optimise IVF timing, predict ovulation and improve scheduling efficiency. The technology supports scalable fertility care, reduced monitoring needs and better patient treatment experiences globally.
The Ferring Global Fertility Monitor has been launched by Ferring Pharmaceuticals and Gallup to examine fertility trends in 70 countries. Through large-scale surveys, the project will explore economic, social, and cultural influences on parenthood decisions. Insights are expected to guide policy, healthcare planning, and future demographic strategies.
Maven Clinic has expanded its Fertility and Family Building program with earlier diagnostics, wearable integration, and AI-powered personalised care. The enhanced platform supports faster diagnosis, improved treatment decisions, and condition-specific pathways for PCOS, endometriosis, and oncofertility. The rollout continues through 2026 with added innovations and partnerships.
Germany is debating the legalization of egg donation in Germany, challenging decades-old restrictions under the Embryo Protection Act. Experts argue reform is overdue to align with modern reproductive science, reduce fertility tourism, and improve patient care, while policymakers work to balance ethical concerns with growing demand for advanced fertility treatments.
A new review highlights the link from Forever Chemicals to reduced ART outcomes, showing how PFAS exposure impacts fertility, pregnancy, and reproductive health. The findings raise urgent concerns for IVF patients and call for stronger regulation, deeper research, and systemic action to address environmental risks in reproductive medicine.
The 2027 Title X NOFO introduces a major policy shift toward addressing infertility crisis in the U.S. It mandates basic infertility services, expands male reproductive health focus, and promotes education on body literacy and lifestyle factors, aiming to support family formation alongside traditional contraceptive services.
